Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (22521)	1/16/2007 7:40:09 AM
From: technetium	Respond to of 52153

"By isolation I assume you mean isolation of the insulin gene from other crops. This remains at least a theoretical concern for all transgenic plants grown outdoors, but there are no special problems in this regard for the SBS insulin program. SBS can grow their insulin-producing plants indoors. (In fact, that’s where the supplies used in clinical trials to date have been grown.) Growing indoors reduces the yield, but this can be mitigated to some degree with horticultural adjustments. Still, I doubt the company would pursue commercialization if all product were required to be grown indoors." By isolation, I meant purify the product. Isolation of the crop indoors might go over better with consumers, but I don't see how that would work on a commercial scale. What's the yeild per acre?